Researcher Honored for Efforts for Breast Cancer Prevention Study
September 03, 2003
Kelly Kita is recruiting women to participate in the STAR breast cancer prevention study.
A researcher at the James P. Wilmot Cancer Center at the University of Rochester Medical Center was recently honored for her work with women participating in a breast cancer prevention study.
Kelly A. Kita, program coordinator for the Study of Tamoxifen and Raloxifene (STAR), was presented the Stellar Clinical Center Performance Award by the National Surgical Adjuvant Breast and Bowel Program.
Kita is coordinating the Wilmot Cancer Center’s participation in this national study of whether raloxifene, an osteoporosis prevention drug, is as effective in reducing the chance of developing breast cancer as tamoxifen.
The Wilmot Cancer Center is one of 600 centers across the United States, Canada and Puerto Rico working to enroll 22,000 postmenopausal women to participate in this long-term clinical study.
This is the fourth consecutive year that Kita has received this award, which recognizes excellence in clinical research.
Kita, a graduate of University of Buffalo, joined the Community Clinical Oncology Program in 1998.